New Drug Application (NDA)

BACK TO GLOSSARY

As defined by the FDA an NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.  The data gathered during the animal studies and human clinical trials of an Investigational New Drug (IND) become part of the NDA.

The goals of the NDA are to provide enough information to permit FDA reviewer to reach the following key decisions:

  • Whether the drug is safe and effective in its proposed use(s), and whether the benefits of the drug outweigh the risks.
  • Whether the drug's proposed labeling (package insert) is appropriate, and what it should contain.
  • Whether the methods used in manufacturing the drug and the controls used to maintain the drug's quality are adequate to preserve the drug's identity, strength, quality, and purity.

The documentation required in an NDA is supposed to tell the drug's whole story, including what happened during the clinical tests, what the ingredients of the drug are, the results of the animal studies, how the drug behaves in the body, and how it is manufactured, processed and packaged.

About the Author
Proxima CRO Team
Bufo Areh
Clinical Research Associate

Nwabufo obtained his B.Sc. in Biotechnology with a minor in Business Administration from the Richard Stockton University, New Jersey. Nwabufo has over four years of global experience in a variety of therapeutic areas, including cardiovascular, oncology, ophthalmology, infectious diseases, CNS, and metabolic diseases as a clinical research associate.

Related FAQs:
More Questions? We're here to help!
SPEAK WITH A SPECIALIST